安罗替尼联合依托泊苷口服治疗铂类耐药或难治性晚期卵巢癌的临床疗效观察

摘要/Abstract

摘要： 目的：通过观察门诊服用安罗替尼联合依托泊苷胶囊治疗的铂类耐药或难治性晚期卵巢癌患者，分析该联合治疗的疗效和安全性。方法：回顾性分析2018年6月至2020年4月在我科室经病理确诊且对铂类耐药或难治性晚期卵巢癌患者14例，均给予安罗替尼联合小剂量依托泊苷胶囊治疗。收集患者的治疗反应、毒副作用发生情况，计算有效率、疾病控制率、中位无进展生存时间。结果：截至末次随访时间2020年8月31日，部分缓解（PR）患者7例，疾病稳定（SD）患者5例，2例患者进展（PD），总有效率（ORR）为50.0%（7/14），疾病控制率（DCR）为85.7%（12/14）。中位无进展生存时间为6个月（95%CI：0.0，12.7）。14例患者中乏力、腹胀和食欲下降的发生率100%，均为1~2级。白细胞下降的发生率为64.7%，1例患者3级，1例患者4级，经减少依托泊苷服药时间（7 d）后降为1级；高血压的发生率为35.7%，均为1、2级。口腔黏膜炎发生率为21.4%，1例为3级黏膜炎。1例患者因4周期后出现2级窦性心动过缓停止该方案治疗。结论：安罗替尼联合依托泊苷胶囊口服治疗晚期卵巢癌毒副作用可耐受、疾病控制率高。

关键词: font-size:medium, ">安罗替尼；依托泊苷；卵巢癌；疗效；安全性

Abstract: Objective： To observe the efficacy and safety of the combination therapy of anlotinib and etoposide capsules in patients with platinum-resistant or refractory advanced ovarian cancer. Methods： From June 2018 to April 2020， 14 patients with platinum resistant or refractory advanced ovarian cancer confirmed by pathology in our department were retrospectively analyzed. All patients were treated with arotinib combined with low-dose etoposide capsules. Therapeutic reaction and adverse reaction were collected. The effective rate， disease control rate and median progression free survival time were calculated. Results： The last follow-up time was August 31， 2020. There were 7 cases of partial response (PR)， 5 cases of stable disease (SD)， 2 cases of progression of disease (PD)， and the overall response rate (ORR) was 50.0% (7/14)， disease control rate (DCR) was 85.7%(12/14). The median progression-free survival (PFS) was 6.0 months， 95%CI=(0.0， 12.7). The incidence of fatigue， abdominal distension and loss of appetite were all 100% in 14 patients， which were grade 1~2. The incidence of leukopenia was 64.7%， one patient was grade 3 and another was grade 4. After reducing the time of etoposide (7 days)， it was reduced to grade 1.The incidence of hypertension was 35.7%， which was grade 1~2. The incidence of oral mucositis was 21.4%， and 1 case was grade 3. One patient stopped treatment because of grade 2 sinus bradycardia after 4 cycles. Conclusion： The combination of anlotinib with etoposide oral administration shows promising efficacy and manageable toxicities in patients with platinum-resistant or refractory advanced ovarian cancer.

Key words: font-size:medium, ">Anlotinib； Etoposide； Ovarian caner； Efficacy； Safety

中图分类号:

姚书娜, 姚志华, 严正, 王海英, 褚俊峰, 赵爽, 刘艳艳, 杨树军. 安罗替尼联合依托泊苷口服治疗铂类耐药或难治性晚期卵巢癌的临床疗效观察[J]. 中国医药导刊, 2021, 23(2): 100-103.

YAO Shuna, YAO Zhihua, YAN Zheng, WANG Haiying, CHU Junfeng, ZHAO Shuang, LIU Yanyan, YANG Shujun. Clinical Efficacy of Oral Administration of Anlotinib Combined with Etoposide in the Treatment of Patients with Platinum-Resistant or Refractory Advanced Ovarian Cancer[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(2): 100-103.

参考文献

[1]Siegel RL， Miller KD， Jemal A. Cancer statistics， 2018[J]. CA Cancer J Clin， 2018， 68(1)：7-30.
     [2]Bios AD，Reuss A， Pujade-Lauraine E， et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer： a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials[J]. Cancer， 2009， 115(6)：1234-1244.
     [3]Burger RR， Sill MW， Monk BJ， et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer： a Gynecologic Oncology Group Study[J]. J Clin Oncol， 2007， 25(33)：5165-5171.
     [4]Audeh MW， Carmichael J， Penson RT， et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer： a proof-of-concept tria[J]. Lancet， 2010， 376(9737)：245-251.
     [5]Kristeleit R， Shapiro GI， Burris HA， et al. A Phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-Mutated ovarian carcinoma or other solid tumors[J]. Clin Cancer Res， 2017， 23(15)：4095-4106.
     [6]Pignata S， Lorusso D， Scambia G， et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11)： a randomised， open-label， phase 2 trial[J]. Lancet Oncol， 2015， 16(5)：561-568.
     [7]Pujade-Lauraine E， Hilpert F， Weber B， et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer： The AURELIA open-label randomized phase Ⅲ trial[J]. J Clin Oncol， 2014 May 1；32(13)：1302-1308.
     [8]Eisenhauer EA， Therasse P， Bogaerts J， et al. New response evaluation criteria in solid tumours：revised RECIST guideline(version 1.1).Eur J Cancer， 2009， 45：228-247.
     [9][9] National Institute of Cancer. Commom terminology criteria for adverse events(CTCAE)[J]. U.S. Department of Health and Human Services, 2010: 1-71.
     [10]Coleman RL， Brady MF， Herzog TJ， et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent， platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213)： a multicentre， open-label， randomised， phase 3 trial[J]. Lancet Oncol， 2017， 18(6)：779-791.
     [11]González-Martín A， Oza AM， Embleton AC et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer[J]. Gynecol Oncol， 2019， 152(1)：53-60.
     [12]Evans T，Matulonis U. PARP inhibitors in ovarian cancer： evidence， experience and clinical potential[J]. Ther Adv Med Oncol， 2017， 9(4)：253-267.
     [13]Taylor KN， Eskander RN. PARP inhibitors in epithelial ovarian cancer[J]. Recent Pat Anticancer Drug Discov， 2018， 13(2)：145-158.
     [14]Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1):105.
     [15]Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654:77-86.
     [16]Taurin S, Yang CH, Reyes M, et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model[J]. Int J Gynecol Cancer, 2018, 28(1):152-160.
     [17]杨雪晶，宋东，杨晓玲，等.盐酸安罗替尼治疗晚期恶性肿瘤的安全性和有效性分析[J]. 肿瘤研究与临床， 2020， 32（7）：489-492.
     [18]陈倩，赵秧，康马飞，等.安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察[J]. 中国实用医药， 2020， 15（7）：1-3.
     [19]Rose PG， Blessing GA， Mayer AR， et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma： a gynecologic oncology group study[J]. J Clin Oncol， 1998， 16(2)：405-410.
     [20]Emile G， Chauvenel L， Tigaud JM， et al. A clinical experience of single agent bevacizumab in relapsing ovarian cancer[J]. Gynecol Oncol， 2013， 129(3)：459-62.
     [21]Gupta R， Cristea M， Frankel P， et al. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian， fallopian tube， and primary peritoneal cancer[J]. Cancer Treat Res Commun， 2019， 21：100155.
     [22]Lan C， Wang Y， Xiong Y， et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC)： a phase 2， single-arm， prospective study[J]. Lancet Oncol， 2018， 19(9)：1239-1246.
     [23]Han B， Li K， Wang Q， et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer： the ALTER 0303 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol， 2018， 4(11)：1569-1575.
     [24]Han B， Li K， Zhao Y， et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer： a multicentre， randomised phase Ⅱ trial (ALTER0302)[J]. Br J Cancer， 2018， 118(5)：654-661.

快速检索引用检索图表检索高级检索